摘要
心肌梗死是威胁人类健康的主要疾病之一,发病率和死亡率都较高。临床治疗心肌梗死的方法是经皮冠状动脉介入治疗,及时恢复心肌组织缺血区的血液供应,保护心肌细胞活力和功能。然而,血液的再灌注会进一步加速缺血心脏的损伤,造成心肌缺血再灌注损伤(Myocardial ischemia/reperfusion injury,MI/RI)。研究发现MI/RI的病理过程十分复杂,涉及多种机制,但其确切机制尚未完全阐明。因此,阐明其潜在机制,采取安全有效的治疗策略,减少MI/RI中心肌细胞死亡和减少心肌梗死面积,是目前临床上治疗缺血性心肌病亟待解决的问题。越来越多的研究表明NLRP3炎症小体介导的细胞焦亡在MI/RI中扮演着重要角色。传统中医药是我国的瑰宝,具有多成分、多通路、多靶点以及毒副作用小的特点,对于复杂病理机制的缺血性心肌病具有独特的优势和治疗潜能。本文以NLRP3炎症小体和细胞焦亡在MI/RI中的作用,及中药复方、中药粗提取物、活性单体成分的作用及其作用靶点为切入点,对近7年来报道的具有抗MI/RI作用的中药研究进行了系统综述,以期为抗MI/RI治疗药物的进一步开发和应用提供理论支撑。
Myocardial infarction(MI),with high incidence and fatality rate, threatens human health. The clinical therapy for MI is percutaneous coronary intervention, which timely restores blood supply to the ischemic area of myocardium and thus sustains the viability and function of cardiomyocytes. However, blood reperfusion will exacerbate the damage to the ischemic heart, causing myocardial ischemia-reperfusion injury(MI/RI). The pathological process of MI/RI is complex, involving multiple mechanisms, but the exact mechanism has not yet been elucidated. Therefore, it is urgent for the clinical treatment of ischemic cardiomyopathy to unveil the underlying mechanism, develop safe and effective therapeutic strategies, and further reduce cardiomyocyte death and myocardial infarction area in MI/RI. It has been frequently verified that NLRP3 inflammasome-mediated pyrolysis plays an important role in MI/RI. As a treasure of China, traditional Chinese medicine(TCM) has multiple-component, multiple-pathway, and multiple-target characteristics, with low toxic and side effects. Thus, it boasts unique advantages and therapeutic potential for ischemic cardiomyopathy which has complex pathological mechanisms. This study reviews the role of NLRP3 inflammasome and pyroptosis in MI/RI,and the anti-MI/RI Chinese medicine reported in the past seven years, including the Chinese medicine compound formulas, Chinese medicinal crude extracts, their active monomer components, and their mechanisms of action and targets, which is expected to lay a theoretical basis for further development and application of drugs against MI/RI.
作者
栾飞
彭利霞
雷紫琴
杨若聪
饶志粒
曾南
Luan Fei;Peng Lixia;Lei Ziqin;Yang Ruocong;Rao Zhili;Zeng Nan(State Key Laboratory of Southwestern Chinese Medicine Resources,Chengdu University of Traditional Chinese Medicine,Chengdu 611137;School of Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu 611137)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2022年第4期216-228,共13页
Pharmacology and Clinics of Chinese Materia Medica
基金
国家自然科学基金面上项目(编号:82074094)
四川省科技厅应用基础研究项目(编号:20YYJC0640)。
作者简介
通信作者:曾南,教授,博士生导师,从事中药药理学研究,E-mail:19932015@cdutcm.edu.cn;栾飞,博士研究生,从事中药药理学研究,E-mail:luanfeiren@163.com。
